Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics by Vorhies, John S & Nemunaitis, John J
© 2007 Vorhies and Nemunaitis, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Biologics: Targets & Therapy 2007:1(4) 367–376 367
REVIEW
Nucleic acid aptamers for targeting of shRNA-
based cancer therapeutics
John S Vorhies
John J Nemunaitis
Mary Crowley Cancer Research 
Centers, Dallas, TX, USA
Correspondence: John Nemunaitis
1717 Main St, Suite 6000, Dallas, Texas 
75201, USA
Tel +1 214 658 1964
Fax +1 214 658 1992
Email jnemunaitis@marycrowley.org
Abstract: Aptamers are nucleic acid ligands which have been validated to bind to epitopes with 
a speciﬁ  city similar to that of monoclonal antibodies. Aptamers have been primarily investigated 
for their direct function in terms of inhibition of protein targets; however, recent evidence gives 
reason to actively explore aptamers as targeting moieties for delivery of anticancer therapeutics. 
Many aptamers have been developed to bind to extracellular membrane domains of proteins 
overexpressed on cancer cells and have the potential to be modiﬁ  ed for use in targeting cancer 
therapeutics. The use of DNA vector-based short hairpin RNA (shRNA) for RNA interference 
(RNAi) is a precise means for the disruption of target gene expression but its clinical usage in 
cancer is limited by obstacles related to delivery into cancer cells. Nucleic acid aptamers are 
attractive candidates for targeting of shRNA therapies. Their small size, ease of production 
and modiﬁ  cation, and high speciﬁ  city are valued attributes in comparison to other targeting 
moieties currently being tested. Here we review the development of aptamers directed to PSMA, 
Nucleolin, HER-3, RET, TN-C, and MUC1 and focus on their potential for use in targeting of 
shRNA-based cancer therapeutics.
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Introduction
Delivery vehicles optimal for shRNA delivery ideally are targeted in order to maximize 
biodistribution to the cancer cell population, thereby increasing their effectiveness in 
the clinical setting and minimizing potentially adverse off target (ie, nonmalignant) 
cell effects. Tumor cellular uptake at the target site(s) can be enhanced by conferring 
to the delivery vehicle the ability to recognize surface features of the target cells. 
This can be accomplished most readily by recognizing surface antigens or promoting 
receptor mediated endocytosis. Delivery vehicles can be complexed with monoclonal 
antibodies, peptides, small molecule ligands, and aptamers to recognize cell surface 
markers (Lu and Low 2002; Dyba et al 2004; Stefanidakis and Koivunen 2004; Hughes 
and Rao 2005).
Aptamers are noncoding nucleic acid oligomers made from either RNA or DNA. 
Much like tRNA, they fold through intramolecular bonds into varied tertiary structures. 
The folded structure of aptamers creates binding pockets that allow the molecules to 
interact with the three dimensional structure of speciﬁ  c domains on a protein’s surface. 
Aptamers bind to epitopes with afﬁ  nity comparable to that of monoclonal antibodies. 
Their dissociation constants are often in the picomolar to low nanomolar range. Because 
of their high surface area, the area in contact with the target is large, minimizing the 
chances of off target effects by increasing binding speciﬁ  city. In some cases aptamers 
can inhibit the function of a target protein by binding to its active site, or inducing a 
conformational change, or inhibiting dimerization or DNA binding (Lupold et al 2002; 
Umehara et al 2004; Shi et al 2007).Biologics: Targets & Therapy 2007:1(4) 368
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The idea of developing nucleic acid ligands for therapeutic 
purposes was born out of the study of activation of viral gene 
expression during HIV infection. There exists a nucleic acid 
ligand that binds speciﬁ  cally to a transactivator of human 
immunodeﬁ  ciency virus type 1 (HIV-1) gene called Tat. The 
Tat protein normally binds to an RNA stem-loop structure 
called a trans-acting response element (TAR) which occurs 
within the ﬁ  rst 60 nucleotides of all HIV-1 transcripts, thus 
activating expression of viral genes. A series of studies 
showed that overexpression of TAR sequence decoys con-
ferred HIV-1 resistance to cells, presumably because the TAR 
oligonucleotides bound speciﬁ  cally to the Tat protein, thus 
inhibiting it from activating viral gene expression (Sullenger 
et al 1990; Sullenger et al 1991; Held et al 2006).
Since this initial discovery, a wide range of potential 
therapeutic applications for aptamers have been proposed 
and pursued (Bunka and Stockley 2006). Aptamers have been 
successfully developed against extracellular protein ligands, 
such as transforming growth factor receptors, platelet-derived 
growth factor, basic ﬁ  broblast growth factor, and vascular 
endothelial growth factor (VEGF) as well as intracellular 
proteins such as NFkb (Jellinek et al 1995; Golden et al 2000; 
Cassiday and Maher 2001; Pietras et al 2001; Ohuchi et al 
2005, 2006; McCauley et al 2006). Pegaptanib, an aptamer 
that binds to and inhibits VEGF has been approved by the 
FDA for treatment of age related macular generation (Ng et al 
2006). Aptamers that bind to blood coagulation factors VIIa 
and IXa are being investigated as anticoagulants (Rusconi 
et al 2002). A subset of aptamers that have been developed 
for therapeutic purposes have the potential to be used as 
targeting moieties for shRNA.
Aptamers represent an attractive alternative to traditional 
methods of targeting cancer gene therapy by circumventing 
many of the stumbling blocks that inhibit the effectiveness 
of these methods. Aptamers are smaller than monoclonal 
antibodies. With a molecular weight of 10–15 kDa they 
are one order of magnitude lighter than antibodies used for 
targeting, which have an average molecular weight of 150 
kDa (White et al 2000). Aptamers are also less immunogenic 
than antibodies (Drolet et al 2000; Pestourie et al 2005; 
Apte et al 2007), making them more suited to systemic 
administration and long term therapy.
Aptamers can facilitate cell entry of an shRNA delivery 
vehicle in similar ways as traditional targeting moieties. 
Aptamers to the extracellular domains of transmembrane 
receptor proteins can penetrate the cell membrane by 
receptor mediated endocytosis (Hughes and Rao 2005). 
When aptamers bind to cell surface proteins they increase 
the proximity of the delivery vehicle and the cell membrane. 
This facilitates charge interactions between a positively 
charged delivery vehicle and the negatively charged 
membrane that result in internalization of the payload. Here 
we will brieﬂ  y review the process of aptamer development 
and then give examples of the current development of 
aptamers directed to good candidate proteins for tumor 
targeting.
Here we review the development of aptamers directed 
to PSMA, Nucleolin, HER-3, RET, TN-C, and MUC1 and 
focus on their potential for use in targeting of shRNA-based 
cancer therapeutics. Though most of these aptamers have not 
yet been used as shRNA targeting moieties in vivo this selec-
tion of aptamers represents a group that is well suited to the 
targeting shRNA-based cancer therapies thereby enhancing 
their efﬁ  ciency and safety.
Aptamer production
RNA and DNA aptamers with speciﬁ  c binding properties 
can now be ampliﬁ  ed in vitro from libraries through a 
streamlined, automated iterative selection process. Because 
of their small, relatively simple structure, the chemical 
modiﬁ  cation of aptamers to increase serum stability or 
bioavailability can be accomplished readily. The produc-
tion and modiﬁ  cation of aptamers is very uncomplicated 
when compared to the production of monoclional antibod-
ies, which require prokaryotic or eukaryotic expression 
systems. The chemical methods involved are well deﬁ  ned 
and easily conformable to good manufacturing process 
requirements, which has eased the transition of aptamers 
into the clinical setting.
Aptamers that bind to a speciﬁ  c target are isolated from 
a group of candidate oligonucleotides, either RNA or DNA, 
through ‘systematic evolution of ligands by exponential 
enrichment’ (SELEX) (Tuerk and Gold 1990). SELEX 
is an in vitro process that can be automated to allow the 
rapid production of aptamers (Cox et al 2002; Ellington 
et al 2005).
The SELEX process begins with a degenerate sequence 
library of 1015 molecules. With a library of this size it is 
likely that there is a molecule that will bind to almost any 
target (Ellington and Szostak 1990). The library is then 
treated with the target molecule at physiological pH and 
temperature. After some aptamers bind the aptamer–target 
complexes are partitioned from the nonbinding aptamers 
and bound species are regenerated and ampliﬁ  ed by PCR in 
the case of DNA aptamers or RT-PCR in the case of RNA 
aptamers. The ampliﬁ  ed molecules are then subjected to Biologics: Targets & Therapy 2007:1(4) 369
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another round of the selection process. Over this repetitive 
process of binding and ampliﬁ  cation the pool is enriched for 
aptamers that bind most efﬁ  ciently to the target (Gopinath 
2007). SELEX can also be tailored by ligation and cleavage 
of small 10nt ﬁ  xed primer sites before and after ampliﬁ  ca-
tion. These smaller primer sequences allow the isolation of 
shorter aptamer sequences which can later be more readily 
synthesized chemically (Vater et al 2003).
Whole-cell SELEX is a procedure that has been developed 
for the selection of aptamers to extracellular matrix proteins 
and transmembrane proteins. It involves the introduction of 
cells overexpressing the protein target of interest to oligomer 
libraries. This procedure offers the advantage of selecting 
molecules more suited to recognizing their target in its natural 
glycosylation state under physiological conditions. Because 
of the great variety of proteins of the cell surface, a second 
set of traditional SELEX with the puriﬁ  ed protein is some-
times necessary to obtain a puriﬁ  ed speciﬁ  c aptamer product 
(Hicke et al 2001; Cerchia et al 2005; Ohuchi et al 2005). This 
method has been used to isolate aptamers that bind to human 
transforming growth factor-beta type III receptor displayed 
on cell surface (Ohuchi et al 2005, 2006).
Naked nucleotide oligomers are in general very unstable 
in the blood and are unsuitable for therapeutic or targeting 
applications. One study showed that an unmodiﬁ  ed aptamer 
against thrombin had an in vivo serum half-life of only 
108 seconds (Grifﬁ  n et al 1993). A variety of chemical 
modiﬁ  cations can be applied to nucleic acid aptamers during 
and after the SELEX process in order to increase their 
suitability for systemic tumor targeting (Table 1). Natural 
nucleotides within aptamers can be substituted with 2′ ﬂ  uoro, 
O-methyl, or amino modiﬁ  ed or 4′ thio modiﬁ  ed nucleotides 
that are poor substrates for nuclease degradation (Beigelman 
et al 1995; Gold et al 1995; Burmeister et al 2005; Kato et al 
2005) 3′ end caps can also be modiﬁ  ed to confer nuclease 
resistance (Burmeister et al 2005). Aptamers can be bound 
to bulky lipids or polymers to reduce their renal clearance 
and increase their serum half-life (Boomer et al 2005). 
Aptamer intramolecular bonds can be altered to increase 
structural stability (Schmidt et al 2004). Beyond chemical 
modiﬁ  cations to increase stability, aptamers can also be 
modiﬁ  ed with small functional groups to facilitate their 
attachment as targeting moieties to polymeric or lipid shRNA 
delivery vehicles. Amino groups have been added to aptamers 
in order to facilitate their conjugation to a nanoparticle 
composed of poly(lactic acid)-block-polyethylene glycol 
copolymer with a terminal carboxylic acid functional group 
(Farokhzad et al 2004).
Likely candidates for aptamer 
mediated cancer targeting
The following cell surface proteins are good candidates for 
tumor targeting. Aptamers are actively being developed for 
all of them, whether for therapeutic or for targeting purposes 
(Table 2).
Prostate-speciﬁ  c membrane antigen 
(PSMA)
The most extensively studied aptamer for cancer targeting 
binds to the prostate-speciﬁ  c membrane antigen (PSMA). 
PSMA is a well described protein that is expressed in prostate 
cancer epithelial cells (Israeli et al 1994; Murphy et al 1998). 
Its use in targeting of many different types of cancer thera-
peutics is a constantly developing ﬁ  eld. In normal prostate 
epithelial cells, it is primarily expressed as the intracellular 
protein referred to as PSM’ but in prostate carcinoma the 
splice variant termed PSMA is overexpressed. PSMA, which 
is more pertinent for targeting purposes, is a type 2 integral 
membrane glycoprotein folate carboxypeptidase expressed 
exclusively in prostate acinar epithelium (Su et al 1995). 
Increased PSMA expression has been documented in pros-
tatic intraepithelial neoplasia, prostatic adenocarcinoma, and 
in tumor associated neovasculature. Its expression generally 
increases with disease progression and metastasis (Bostwick 
et al 1998).
PSMA was originally described as the target for mAb 
7E11in the androgen-dependent LNCaP human prostatic 
adenocarcinoma cell line (Horoszewicz et al 1987). 
Antibodies that bind to the extracellular domain of the PSMA 
are used clinically for imaging and staging of prostate cancer 
(Freeman et al 2002) and are in clinical trials to determine 
therapeutic potential (Bander et al 2005). Monoclonal 
antibodies to PSMA have also been used to target delivery 
of gene therapy in vivo (Moffatt et al 2006).
The practicality of PSMA as a target for various kinds of 
anticancer therapies has placed it in center stage of aptamer-
based cancer targeting research. The ﬁ  rst reported RNA 
aptamers selected to bind a tumor-associated membrane 
antigen were two 2′-ﬂ  uoro-pyrimidine RNA oligomers that 
bind to the extracellular domain of the PSMA. These two 
aptamers, called xPSM-A9 and xPSM-A10, which share no 
consensus sequences, bind to the PSMA at different extracel-
lular epitopes. Aptamer xPSM-A9 was shown to inhibit the 
PSMA noncompetitively with an average K(i) of 2.1 nM, 
while aptamer xPSM-A10 inhibits the PSMA competitively 
with an average K(i) of 11.9 nM (Lupold et al 2002).Biologics: Targets & Therapy 2007:1(4) 370
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The nuclease resistant xPSMA-A10 aptamer has been 
exploited to target the delivery of various nanoparticulate 
drug delivery systems. It has peen particularly well studied 
as a targeting moiety for biodegradable nanoparticles conju-
gated with chemotherapeutics. In one study, the xPSMA-A10 
aptamer was bound to a poly(lactic acid)-block-polyethylene 
glycol (PEG) copolymer with a terminal carboxylic acid 
functional group (PLA-PEG-COOH) and used to deliver 
rhodamine-labeled dextran as a model drug in vitro. This 
study showed that the targeted nanoparticles preferentially 
bind to and are taken up in vitro by LNCaP prostate epithelial 
cells which express PSMA, but not by PC3 prostate epithelial 
cells, which do not express detectable levels of the PSMA 
(Farokhzad et al 2004).
In a more recent study, 5′-NH2 modiﬁ  ed xPSMA-A10 
aptamers were conjugated to poly(D,L-lactic-co-glycolic 
acid)-block-poly(ethylene glycol) nanoparticles with 
terminal carboxylic acid groups (PLGA-PEG-COOH). 
Table 1 Common chemical modiﬁ  cations of aptamers for tumor targeting
Modiﬁ  cation  Effect  Reference
surround with lipoproteins  Reduced renal clearance  Willis 1998
PEGylation  Reduced renal clearance  Boomer 2005
binding to cholesterol  Reduced renal clearance  Rusconi 2004 de Smidt 1991
biotin–streptavidin  Reduced renal clearance  Dougan 2000
2′-ﬂ  uoro pyrimidine substitution  Nuclease resistance  Burmeister 2005
2′-O-methyl nucleotide substitution  Nuclease resistance  Chelliserrykattil 2004 Beigelman 1995 Burmeister 2005
3′ end cap modiﬁ  cation  Nuclease resistance  Burmeister 2005
2′-amino nucleotide substitution  Nuclease resistance  Burmeister 2005
use of locked nucleic acid modﬁ  cation  Improve structural stability  Schmidt 2004
4′thio nucleotide substitution  Nuclease resistance  Kato 2005
3′-amino nucleotide substitution  Facilitation of conjugation to delivery vehicle  Lupold 2002
de Smidt PC, Doan TL, de Falco S and van Berkel TJC. 1991. Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modiﬁ  es the tissue 
distribution. Nucleic Acids Res,19, 4695–700.
Dougan H. et al. 2000. Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl Med Bio, 27, 289–97.
Boomer RM. et al. 2005. Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inﬂ  amed tissues. Oligonucleotides, 15, 183–95.
Willis MC. et al. 1998. Liposome anchored vascular endothelial growth factor aptamers. Bioconjug Chem, 9, 573–82.
Beigelman L, McSwiggen JA, Draper KG, Gonzalez C, Jensen K, Karpeisky AM, Modak AS, Matulic-Adamic J, DiRenzo AB, Haeberli P, et al. 1995. Chemical modiﬁ  cation of 
hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem. Oct 27;270(43):25702-8. PMID: 7592749.
Burmeister PE, Lewis SD, Silva RF, Preiss JR, Horwitz LR, Pendergrast PS, McCauley TG, Kurz JC, Epstein DM, Wilson C, Keefe AD. 2005. Direct in vitro selection of a 2′-O-
methyl aptamer to VEGF. Chem Biol, 12:25–33.
Rusconi CP, Roberts JD, Pitoc GA, Nimjee SM, White RR, Quick G Jr, Scardino E, Fay WP, Sullenger BA. 2004. Antidotemediated control of an anticoagulant aptamer in vivo. 
Nat Biotechnol, 22:1373–84.
Kato, Y. et al. 2005. New NTP analogs: the synthesis of 4′-thioUTP and 4′-thioCTP and their utility for SELEX. Nucleic Acids Res,33, 2942–51.
Table 2 Nucleotide aptamers in development with potential for use in targeting of shRNA therapy
Aptamer Target  Testing     
    in vitro  in vivo  Clinical
AS1411  Nucleolin  antiproliferation, growth  Antitumor activity in nude mouse  Phase 1 and 2 trials
(Agro100)    inhibition  xenograft models, synergy  for advanced
      with chemotherapeutic agents  solid malignancies
TTA1  TN-C  Binding   Sucessful aptamer penetration  not tested
      in various murine xenograft 
     tumor  models 
various  MUC1  Binding  Sucessful aptamer penetration  not tested
      in a murine xenograft tumor model 
xPSM-  PSMA  Inhbition of PSMA via   Sucessful targeting of a  not tested
A10    competetive binding   chemotherapy nanoparticle in 
      a murine xenograft model 
xPSM-A9   PSMA  Inhbition of PSMA via   not tested   not tested
   noncompetetive  binding   
A30  HER3  Inhibitor of HER-3 signaling  not tested  not tested
    via noncompetetive binding   
D4 RETC634Y  Inhibitor of RETC634Y dimer  not tested  not tested
   formationBiologics: Targets & Therapy 2007:1(4) 371
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These nanoparticles were then encapsulated with the 
chemotherapeutic docetaxel and tested in vitro and in vivo. 
The docetaxel-encapsulated nanoparticle-aptamer (Dtxl-
NP-Apt) bioconjugates enhanced in vitro cellular toxicity 
with LNCaP prostate epithelial cells as compared with 
nanoparticles that lack the PSMA aptamer. After a single 
intratumoral injection of Dtxl-NP-Apt bioconjugates using a 
murine LNCaP xenograft model of prostate cancer, complete 
tumor reduction was noted in ﬁ  ve of seven nude mice. 100% 
of the mice that received the Dtxl-NP-Apt bioconjugate sur-
vived the 109-day study. In contrast, only two of seven mice 
that received the non-targeted Dtxl-NP had complete tumor 
reduction and only 57% of the mice in this group survived 
the 109-day study. Only 14% of mice treated with Dtxl alone 
survived the 109-day study (Farokhzad et al 2006). A similar 
study tested PLGA-PEG-COOH-xPSMA-A10 conjugates 
encapsulating docetaxel and 14C labeled paclitaxel. It was 
found that the surface association of nanoparticles with 
targeting aptamer signiﬁ  cantly enhanced delivery to tumors 
when compared to equivalent but nontargeted nanoparticles 
in a murine LNCaP xenograft model (Cheng et al 2007).
PSMA aptamers are particularly attractive as targeting 
moities for RNAi-based cancer therapeutics because the 
PSMA itself participates in membrane recycling, becoming 
internalized through ligand induced endocytosis, thus facili-
tating entry of the therapeutic payload into the cytoplasm 
(Ghosh and Heston 2004). This property of the PSMA has 
been exploited in the targeting of therapeutic siRNAs to pros-
tate cancers using aptamer-siRNA chimeras and conjugates. 
In one study, a 27mer anti-Lamin siRNA was noncovalently 
bound to xPSMA-A9 aptamers using a modular streptavidin 
bridge and tested in vitro to transfect PC3 cells and LNCaP 
cells that naturally expressed the PSMA. The conjugates were 
successfully transfected with this method and inhibition of 
lamin expression was achieved. The conjugates displayed 
similar transfection efﬁ  ciency to oligofectamine controls 
but better speciﬁ  city, as they were only taken up by PSMA 
expressing LNCaP cells and not PSMA-negative PC3 cells 
(Chu et al 2006).
In another study, aptamer-siRNA chimeras were used 
to target prostate cancer cells and knock out expression of 
survival genes. Chimeras of the xPSMA-A10 aptamer and 
polo-like kinase 1 (PLK1) and BCL2 siRNAs were gener-
ated via in vitro transcription from DNA templates. The 
chimeras were shown be internalized and promote apoptosis 
preferentially in PSMA expressing LNCaP cells and not PC3 
control cells. This speciﬁ  city was retained in murine LNCaP 
xenograft tumor models where chimeras bearing PLK1 
siRNAs mediated pronounced tumor regression while having 
no statistically signiﬁ  cant effect on non-PSMA expressing 
PC3 xenografts (McNamara et al 2006).
Nucleolin
An aptamer (AS1411) that binds to the external domain of the 
membrane protein nucleolin is has been well characterized 
because of its therapeutic potential. Due to the properties of 
the aptamer and the properties of nucleolin itself AS1411 
is an excellent candidate for aptamer mediated targeting of 
gene therapy.
Human nucleolin is an abundant multifunctional 76 kDa 
membrane associated phosphoprotein that has 707 amino 
acids in its sequence (Derenzini et al 1995; Sarcevic et al 
1997). It is composed of three main domains, an acidic 
histone-like NH2 terminus, a central domain containing four 
RNA-binding sub-domains, and a carboxy terminal domain 
that contains its four sites of phosphorylation (Lapeyre 
et al 1987; Ginisty et al 1999). Though it was originally 
characterized as a nucleolar protein, nucleolin is also present 
on the external cell membrane where it functions as a 
signaling receptor of poorly deﬁ  ned function (Hovanessian 
et al 2000; Storck et al 2007).
Though its function on the surface of cancer cells has 
not been clearly deﬁ  ned, Nucleolin has been extensively 
investigated in the context of cancer. It has been shown 
to be associated with survival, growth and proliferation of 
cells, nuclear transport, transcription, packing and transport 
of rRNA, and replication and recombination of DNA 
(Srivastava and Pollard 1999). In addition, overexpression 
of nucleolin is related to poor clinical prognosis for some 
cancer types (Derenzini et al 1995; Derenzini 2000).
One pathophysiologic function of cell surface nucleolin 
that makes it ideal for targeting anticancer therapies is its 
involvement in internalization of speciﬁ  c ligands. Nucleolin 
has been shown to bind to and internalize the heparin-binding 
growth factor midkine (Said et al 2002), the iron-binding 
lycoprotein lactoferrin (Legrand et al 2004), acharan sulfate 
(Joo et al 2005), as well as the tumor-homing 34-amino acid 
peptide (F3) (Christian et al 2003).
The aptamer known as AS1411 was ﬁ  rst developed as 
AGRO100 by Aptamera (Louisville, KY). It is an unmodiﬁ  ed 
guanosine rich 26-mer, which binds to nucleolin. AS1411 
was originally investigated because of observations that 
guanosine-rich oligonucleotides (GRO) had nonantisense-
based in vitro antiproliferative properties against cancer cells 
(Bates et al 1999). These oligonucleotides were further stud-
ied and it was found that the unmodiﬁ  ed DNA phosphodiester Biologics: Targets & Therapy 2007:1(4) 372
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GRO analog GRO29A-OH, which retains the G quartet 
structure essential for nucleolin binding (Dapic et al 2003), 
displayed resistance against serum nuclease degradation 
(Dapic et al 2002). AS1411 is simply GRO29A-OH with its 
three 5′ thymidines cleaved.
A nontraditional aptamer because of its G quartet-based 
binding to its target, AS1411 has been shown to bind to cell 
surface nucleolin and inhibit growth of many cancer cell 
lines in vitro such as the prostate cancer cell line DU145, the 
breast cancer cell lines MDA-MB-231 and MCF-7, the lung 
cancer cell line A549, as well as the cervical cancer cell line 
HeLa (Bates et al 1999; Dapic et al 2002).
In anticipation of its use as a therapeutic, biodistribution 
studies were realized to characterize the in vivo pharma-
codymanics, distribution, and metabolism of the aptamer 
following IV administration. AS1411 metabolism was stud-
ied in mice bearing lung and renal human tumor xenografts 
derived from A549 and A498 cells using IV administration 
of AS1411 radiolabeled with tritiated thymidine. Follow-
ing 1, 10, and 25 mg/kg IV boluses of [3H]AS1411, 63% 
of the radiolabeled aptamer was excreted in urine within 
5 hours while less than 1% of the injected dose was detected 
upon analysis of bile, thus suggesting that the main mode 
of metabolism is renal. This same study also showed that 
AS1411 displayed dose related pharmacokinetics with an 
elimination half life of 2 days in plasma and whole blood. 
Regardless of the dose administered, tumor/blood ratios 
were 4:6 for the renal carcinoma xenograft and 2:4 and for 
the lung carcinoma xenograft, showing that the aptamer 
effectively accumulated in tumor tissue (Ireson and Kelland 
2006).
In vivo xenograft efﬁ  cacy studies have collectively shown 
that AS1411 results in cytostasis rather than cytotoxicity. 
After treatment with AS1411 cells are blocked at S-phase. 
Because of this observation, there has been interest in com-
bining AS1411 with nucleoside analogs such as gemcitabine, 
which act on cells during S-phase. Early in vitro and in vivo 
studies of AS1411 in combination with gemcitabine against 
PANC-1 pancreatic cancer cells have shown enhanced anti-
tumor activity in comparison to either agent alone (Ireson 
and Kelland 2006).
Preclinical toxicology of AS1411 has been evaluated 
in rats and dogs with IV bolus dosages of up to 100 mg/kg 
in rats and 96-hour continuous IV infusions at doses up to 
10 mg/kg/d. No signiﬁ  cant toxicity was observed in either 
species, as determined by clinical observations, clinical 
pathology evaluation, and gross examination of tissues at 
necroscopy (Ireson and Kelland 2006).
AS1411 was the first nucleic acid-based aptamer 
approved for Phase I clinical testing for the treatment of can-
cer in humans. Results have been published on the progress 
of 17 patients with advanced solid tumors receiving AS1411 
at the Brown Cancer Center in Louisville, KY (Laber et al 
2005). This report describes a continuous IV infusion dose 
escalation study starting from 1 mg/kg/d and thus far reported 
up to 10 mg/kg/d. Fifteen patients received a 4 day infusion 
while 2 patients received a 7 day infusion. No serious toxicity 
related to AS1411 administration was observed. A patient 
with renal cancer achieved a sustained partial response at 16 
months post-treatment and 41% of patients were reported to 
have stable disease at 2 months post-treatment. From these 
initial results the Phase I study has continued with a focus on 
renal and non–small cell lung cancers (Ireson and Kelland 
2006; Laber et al 2006).
The extensive preclinical and burgeoning clinical data 
amassed about AS1411 makes it an ideal candidate for tar-
geting of cancer gene therapy in humans.
Human epidermal growth factor receptor 
3 (HER-3)
Human epidermal growth factor receptor 3 (HER-3) is a 
receptor tyrosine kinase that is overexpressed on the surface 
of many different cancer cells (Yokota et al 1988; Schneider 
et al 1989; Slamon et al 1989; Berchuck et al 1990; Dougall 
et al 1993). The extra-cellular domains of receptor tyrosine 
kinases are rational and accessible targets for anticancer 
therapies. The most prominent example of a therapy targeted 
to the extra-cellular domain of a receptor tyrosine kinase is 
Herceptin, a humanized monoclonal antibody that targets the 
extra-cellular domain of HER-2. This molecule has proved 
effective in the treatment of HER2-overexpressing breast 
cancers (Pegram et al 1999).
An aptamer to the extracellualar domain of HER-3, called 
A30, has been isolated using SELEX. A30 was demonstrated 
to have high binding specificity to HER-3, despite the 
sequence similarities shared by the extracellular domains of 
HER-2 and HER-3. In vitro, A30 inhibits the growth stimu-
latory effects of HER-3’s natural ligand, heregulin, though 
it does not compete for its binding site. A30 also inhibits 
HER-3 from binding to HER-2 which is a necessary step in 
HER-mediated growth induction (Chen et al 2003).
Though A30 is still in the early stages of development 
and would likely need to undergo modiﬁ  cations to enhance 
its serum stability prior to its introduction in the clinical 
setting, it represents a possible future targeting moiety for 
shRNA delivery in the therapy of cancer.Biologics: Targets & Therapy 2007:1(4) 373
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RET
Another receptor tyrosine kinase for which an aptamer has 
been developed is the RET oncoprotein. Mutated forms of 
the RET Receptor tyrosine kinase are implicated as the cause 
of the dominant inherited cancer syndrome MEN2 (Hansford 
and Mulligan 2000). In MEN2, germline to ‘missense muta-
tions of the RET gene result in the conversion of cysteine 
634 to tyrosine (RETC634Y), which causes cancers of the 
neuroendocrine organs. These mutations affect the cysteine 
rich extracellular domain of RET causing the loss of an 
intramolecular disulﬁ  de bond. The loss of this bond allows 
the formation dimmers of mutated RET monomers via an 
intermolecular disulﬁ  de bond. Dimerization results in a con-
stitutively activated receptor (Iwashita et al 1999).
Using 16 cycles of whole-cell SELEX several RNA aptam-
ers that bind to the extracellular domain of RETC634Y have been 
isolated. PC12 cells which expressed the mutant receptor were 
used for the selection procedure. The aptamer with the best sig-
naling inhibition and the most nuclease resistance, termed D4, 
was selected for further development (Cerchia et al 2005).
An aptamer that binds speciﬁ  cally to RET could be useful 
for targeting of speciﬁ  c anticancer gene therapies and it also 
is another example of the use of whole-cell SELEX to effec-
tively develop aptamers that bind to transmembrane proteins 
in their natural glycosylation states. This method could be 
employed to develop aptamers to other potential targets.
Tenascin-C (TN-C)
Tenascin-C is a hexameric extracellular matrix protein that is 
highly expressed during active tissue development processes 
including wound healing, angiogenesis, embryonic develop-
ment, and tumor growth (Mackie et al 1988; Erickson and 
Bourdon 1989; Koukoulis et al 1991; Zagzag et al 1995). 
TN-C is an ideal candidate for targeting of anticancer shRNA 
therapy because it is highly expressed in tumor and in general its 
expression is expression is limited in normal tissues (Borsi et al 
1992). High TN-C expression has been noted in osteosarcomas, 
lymphomas, glioblastomas, melanomas as well as carcinomas 
of breast, colon lung, and prostate (Chiquet-Ehrismann 2004; 
Orend 2005; Orend and Chiquet-Ehrismann 2006).
Using SELEX with TN-C expressing U251 glioblastoma 
cells RNA aptamers that bind to the extracellular ﬁ  brinogen-
like domain of TN-C with high afﬁ  nity were isolated. Several 
modiﬁ  cations were made to the aptamer in order to increase 
its usefulness as a targeting moiety. Its size was reduced in 
order to increase tissue penetration and efﬁ  ciency of syn-
thesis. It was 2′-OCH3 substituted, and 3′ capped in order 
to increase nuclease stability. A 5′ amine was also added to 
serve as a conjugation site. After these modiﬁ  cations the 
resultant aptamer, termed TTA1, had an increased equilib-
rium Kd but the ﬁ  nal value of 5 × 10-9M still represents a 
very high afﬁ  nity (Hicke et al 2001).
In a later experiment the potential of TTA1 to be used for 
in vivo drug delivery was evaluated. Uptake and tumor distri-
bution of rhodamine red-X-labeled TTA1 was studied using 
ﬂ  uorescence microscopy in a U251 human glioblastoma cell 
line xenograft nude mouse model. Within 10 minutes after 
IV injection of the ﬂ  uorescently labeled aptamer, bright 
perivascular ﬂ  uorescence was noted in the xenografts. The 
ﬂ  uorescence then diffused throughout the tumor stroma over 
the following 3 hours (Hicke et al 2006).
Biodistribution and radioimaging studies were performed 
using (99m)Tc labeled TTA1 and glioblastoma (U251) and 
breast cancer (MDA-MB-435) tumor xenografts in nude 
mice. IV administered (99m)Tc labeled TTA1 showed rapid 
blood clearance with a serum half-life of less than 2 min, 
and rapid tumor penetration. TTA1 was cleared much more 
rapidly from the blood than from the tumor. Both renal 
and hepatobiliary clearance pathways were observed, but 
it is estimated that due to rapid nuclease degredation of the 
aptamer the clearance patterns observed were those of the 
aptamer metabolites. In these studies it was found that TTA1 
affectively targeted a wide variety of TN-C expressing tumor 
types including colon (SW620), breast (MDA-MB-468, 
MDA-MB-435), glioblastoma (U251), rhabdomyosarcoma 
(A673). As a control TTA1 was also tested with a squamous 
cell carcinoma of the head and neck (KB) xenograft that 
did not express TN-C. As expected, KB xenografts did not 
display appreciable aptamer uptake (Hicke et al 2006).
The results of these studies are promising in terms of 
TTA1s potential use in tumor targeting. Before its use in 
targeting of shRNA-based cancer therapies it would prob-
ably need further modiﬁ  cations to increase its serum half life. 
While short half lives and rapid elimination are beneﬁ  cial for 
minimizing potential toxicity, such a short serum half life 
may inhibit aptamer penetration in areas of the target tumor 
that are poorly perfused (Hicke et al 2006).
MUC1
MUC1 is a large, highly glycosylated transmembrane 
epithelial cell surface protein. Mucin proteins are expressed 
on the apical membrane of various epithelial cell types. They 
have many roles which facilitate the function of mucosal 
cells such as lubrication of epithelial cell surfaces, prevention 
of tissue dehydration, protection of cells from proteolytic 
degradation and provision of a barrier against infection Biologics: Targets & Therapy 2007:1(4) 374
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(von Mensdorff-Pouilly et al 2000). Mucins also function 
as signal transduction receptors involved in triggering 
cellular responses such as proliferation, differentiation, and 
apoptosis (Taylor-Papadimitriou et al 1999; Hollingsworth 
and Swanson 2004). MUC1 overexpression has been well 
documented in many human adenocarcinomas including 
breast, pancreatic, ovarian, colorectal, lung, prostate, esopha-
geal (Maeshima et al 1997; Aoki et al 1998; Zhang et al 
1998; Hough et al 2000; Ginestier et al 2002; Kohlgraf et al 
2003; Burjonrappa et al 2007). Its expression has also been 
documented in other types of tumors including astrocytoma, 
melanoma, neuroblastoma, as well as hematological malig-
nancies (Oosterkamp et al 1997; Brossart et al 2001).
The cell surface expression pattern of MUC1 across 
human malignancies makes it an excellent and versatile target 
for cancer targeting with an aptamer. Using 10 rounds of in 
vitro SELEX, a group of DNA aptamers has been isolated 
that binds selectively to synthetic MUC1 peptides. This pool 
of aptamers, when ﬂ  uorescently labeled has been veriﬁ  ed to 
bind speciﬁ  cally to MUC1 expressing cancer cell lines in vitro 
(Ferreira et al 2006). In a later study this group of aptamers was 
demonstrated by radio-imaging to have good tumor penetration 
in a murine xenograft (Perkins and Missailidis 2007). These 
aptamers are in the early stages of development and before their 
transition into the clinic they would need further modiﬁ  cation 
to minimize size and maximize nuclease resistance.
Conclusions
Aptamer development could ameliorate many of the traditional 
problems with the introduction of exogenous genetic material 
for therapeutic purposes. There is a wide range of experimen-
tation occurring, from the laboratory to the preclinical setting, 
which has the potential to revolutionize the targeting of gene-
based therapy. The aptamers reviewed here represent the most 
promising areas of current development pertinent to aptamer-
based targeting of shRNA cancer therapeutics and will likely be 
among the ﬁ  rst to make transition to targeting in the clinic.
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